Honokiol decreases alpha-synuclein mRNA levels and reveals novel targets for modulating alpha-synuclein expression.
Parkinson’s disease
SNCA
alpha-synuclein (αSyn)
natural compound
polyphenol
therapeutic target
Journal
Frontiers in aging neuroscience
ISSN: 1663-4365
Titre abrégé: Front Aging Neurosci
Pays: Switzerland
ID NLM: 101525824
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
03
2023
accepted:
17
07
2023
medline:
28
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
Intracytoplasmic inclusions comprised of aggregated alpha-synuclein (αsyn) represent a key histopathological feature of neurological disorders collectively termed "synucleinopathies," which includes Parkinson's disease (PD). Mutations and multiplications in the Human neuroglioma cells stably overexpressing αsyn, mouse primary neurons, and human iPSC-derived neurons were exposed to HKL and αsyn protein and We demonstrate that HKL can successfully reduce αsyn protein levels and This study supports a HKL-mediated downregulation of
Sections du résumé
Background
UNASSIGNED
Intracytoplasmic inclusions comprised of aggregated alpha-synuclein (αsyn) represent a key histopathological feature of neurological disorders collectively termed "synucleinopathies," which includes Parkinson's disease (PD). Mutations and multiplications in the
Methods
UNASSIGNED
Human neuroglioma cells stably overexpressing αsyn, mouse primary neurons, and human iPSC-derived neurons were exposed to HKL and αsyn protein and
Results
UNASSIGNED
We demonstrate that HKL can successfully reduce αsyn protein levels and
Conclusion
UNASSIGNED
This study supports a HKL-mediated downregulation of
Identifiants
pubmed: 37637959
doi: 10.3389/fnagi.2023.1179086
pmc: PMC10449643
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1179086Informations de copyright
Copyright © 2023 Fagen, Burgess, Lim, Amerna, Kaya, Faroqi, Perisetla, DeMeo, Stojkovska, Quiriconi, Mazzulli, Delenclos, Boschen and McLean.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Pharmacol. 2008 Sep 4;591(1-3):43-51
pubmed: 18588872
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14524-9
pubmed: 12376616
Oxid Med Cell Longev. 2016;2016:8378613
pubmed: 26881043
Exp Neurol. 2014 Mar;253:16-27
pubmed: 24374061
ACS Chem Neurosci. 2020 Dec 16;11(24):4469-4477
pubmed: 33185419
Front Neurosci. 2018 Jul 04;12:452
pubmed: 30022929
J Nat Med. 2009 Jul;63(3):274-82
pubmed: 19343477
Science. 1997 Jun 27;276(5321):2045-7
pubmed: 9197268
Biomed Res Int. 2019 Apr 7;2019:8748253
pubmed: 31080832
Science. 2003 Oct 31;302(5646):841
pubmed: 14593171
Drugs. 2019 Jun;79(8):797-810
pubmed: 30982161
Science. 2012 Nov 16;338(6109):949-53
pubmed: 23161999
Cancers (Basel). 2019 Dec 22;12(1):
pubmed: 31877856
Mol Neurodegener. 2015 Mar 19;10:10
pubmed: 25886309
Front Chem. 2018 May 25;6:181
pubmed: 29888220
J Nutr Biochem. 2011 May;22(5):476-86
pubmed: 20688501
Mol Ther. 2018 Nov 7;26(11):2638-2649
pubmed: 30266652
Neuron. 2019 Dec 4;104(5):869-884.e11
pubmed: 31648898
Sci Rep. 2019 May 21;9(1):7567
pubmed: 31110191
J Parkinsons Dis. 2013 Jan 1;3(3):255-69
pubmed: 23948989
Brain. 2014 May;137(Pt 5):1496-513
pubmed: 24662516
Mov Disord. 2016 Feb;31(2):161-8
pubmed: 26347034
Pharmacol Rep. 2018 Aug;70(4):668-676
pubmed: 29909247
Neuron. 2022 Feb 2;110(3):436-451.e11
pubmed: 34793693
Pharmacogn Rev. 2012 Jul;6(12):81-90
pubmed: 23055633
Nature. 1997 Aug 28;388(6645):839-40
pubmed: 9278044
Phytother Res. 2010 Oct;24(10):1538-42
pubmed: 20878707
Mov Disord. 2017 Feb;32(2):203-207
pubmed: 28218461
Biomed Pharmacother. 2018 Dec;108:254-262
pubmed: 30223096
Sci Rep. 2015 Sep 01;5:13556
pubmed: 26324190
J Neurosci Res. 2007 Feb 1;85(2):351-63
pubmed: 17131421
Brain Res. 2009 Dec 11;1305:108-17
pubmed: 19815000
Molecules. 2010 Sep 16;15(9):6452-65
pubmed: 20877235
Nature. 2011 Nov 06;480(7378):547-51
pubmed: 22056989
Expert Opin Ther Targets. 2015 May;19(5):589-603
pubmed: 25785645
Neurobiol Dis. 2018 Jul;115:101-114
pubmed: 29649621
Brain Res. 2020 Mar 1;1730:146672
pubmed: 31953211
Ther Adv Neurol Disord. 2009 Nov;2(6):20-8
pubmed: 21180627
Acta Neuropathol. 2012 Sep;124(3):325-38
pubmed: 22806825
PLoS One. 2011 Apr 29;6(4):e18490
pubmed: 21559510
Mol Ther Nucleic Acids. 2017 Dec 15;9:57-68
pubmed: 29246324
Neuro Oncol. 2012 Mar;14(3):302-14
pubmed: 22259050
J Neurochem. 2019 Sep;150(5):612-625
pubmed: 31055836
Brain Commun. 2021 Oct 22;3(4):fcab247
pubmed: 34761222
Mov Disord. 2019 Aug;34(8):1154-1163
pubmed: 31211448
Neurotherapeutics. 2016 Jan;13(1):179-89
pubmed: 26494242
Mov Disord. 2016 Feb;31(2):214-24
pubmed: 26260853
Free Radic Biol Med. 2013 Sep;62:111-120
pubmed: 23328732
Mol Cell. 2009 Aug 28;35(4):467-78
pubmed: 19716791
Front Neurol. 2013 Sep 11;4:130
pubmed: 24062717
Cell. 2005 Oct 21;123(2):249-63
pubmed: 16239143
J Pharmacol Exp Ther. 2018 Sep;366(3):470-478
pubmed: 29991481
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13052-7
pubmed: 19628698
J Clin Med. 2020 Apr 08;9(4):
pubmed: 32276438
J Neurochem. 2019 Sep;150(5):566-576
pubmed: 31265132
Adipocyte. 2012 Jul 1;1(3):182-187
pubmed: 23700531
PLoS One. 2018 Jan 11;13(1):e0190350
pubmed: 29324783